
Artelo Biosciences Analyst See It As An Emerging Biotech
D. Boral Capital upgraded Artelo Biosciences, Inc. ARTL on Tuesday. The analyst upgraded from Hold to Buy and introduced a price forecast of $20. Analyst Jason Kolbert wrote, “We continue to view Artelo as an emerging biotechnology company focused on …